EV Biologics Corp. announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product. Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6021 USD | -3.21% | 0.00% | -39.79% |
2023 | EV Biologics, Inc. Closes A $500,000 Interest-Free Loan | CI |
2023 | Ev Biologics Completes Production of Cutting-Edge Msc Exosome-Based Therapeutic | CI |
1st Jan change | Capi. | |
---|---|---|
-39.79% | 6.36M | |
+18.72% | 48.44B | |
+8.09% | 16.74B | |
-3.10% | 15.77B | |
-9.17% | 11.23B | |
+32.47% | 9.22B | |
-4.30% | 7.83B | |
+40.74% | 7.65B | |
-5.24% | 7.57B | |
+105.28% | 7.38B |
- Stock Market
- Equities
- YECO Stock
- News EV Biologics, Inc.
- Ev Biologics Completes Production of Cutting-Edge Msc Exosome-Based Therapeutic